Tango Therapeutics price target raised to $13 from $11 at Wedbush

Wedbush analyst Robert Driscoll raised the firm’s price target on Tango Therapeutics to $13 from $11 and keeps an Outperform rating on the shares following Q2 financial results. The firm notes Tango continues to evaluate its PRMT5 inhibitor programs TNG908 and TNG462 in dose expansion studies, and will present a comprehensive update with available data from dose-escalation and expansion in the second half of 2024.